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Introduction
Retinal dystrophies are the leading cause of incurable blind-
ness in developed countries (prevalence 1/3,000 worldwide). 
Over the last decade, retinal dystrophies have demonstrated 
a tremendous clinical, genetic, molecular, and physiopatho-
logical heterogeneity.
Leber congenital amaurosis (LCA, MIM204000) is the ear-
liest and most severe of these disorders. With prevalence 
of 1/60,000 worldwide it is a common cause of blindness in 
childhood (10%).1 It is one of the most representative exam-
ples of retinal dystrophies heterogeneity. Outcome ranges 
from severe stationary cone-rod disease with extremely poor 
visual acuity (VA ≤ light perception; type I) to progressive, 
yet severe, rod-cone dystrophy with measurable VA in the 
first decade of life (20/200 ≤ VA ≤ 60/200; type II).2 Hitherto, 
15 disease genes have been identified which account for 
~70% of the cases. They are either specifically or preferen-
tially expressed in the retinal pigment epithelium or photo-
receptors,  or  widely  expressed.1,3  This  physiopathological 
heterogeneity challenges the development of therapies with 
different retinal cell types to be targeted and variable thera-
peutic windows.
In Western European countries, the centrosomal protein 
290 (CEP290, MIM610142) is the most common LCA gene 
(20%)4,5 and accounts consistently for the most severe dis-
ease phenotype (type I).5 CEP290 encodes an integral com-
ponent of the ciliary gate that bridges the transition zone 
between the cilia and cytoplasm of a broad range of cells 
including  photoreceptors.  The  protein  plays  an  important 
role in maintaining the structural integrity of this gate, and 
thus has a crucial role in maintaining ciliary structure and 
function.6 As a result, in addition to LCA, CEP290 muta-
tions cause a wide range of distinct phenotypes,7 including 
Senior-Loken syndrome (SLNS6, MIM610189), Joubert syn-
drome (JBTS5; MIM610188), Bardet-Biedl syndrome (BBS, 
209900), and the lethal Meckel-Grüber syndrome (MKS4, 
MIM611134).
Despite  the  identification  of  over  100  unique  CEP290 
mutations, no clear genotype-phenotype correlations could 
yet be established7 with the exception of the LCA-specific 
c.2991+1655A>G mutation.4,5 This single mutation accounts 
for 10% of cases5 and represents therefore an important 
therapeutic  target.  It  is  located  deep  in  intron  26  where 
it creates a splice donor downstream of a strong accep-
tor splice site. As a result, a cryptic 128 bp exon encoding 
a stop codon is inserted in the CEP290 messenger RNA 
(mRNA).4
Considering  the  potential  of  exon-skipping  as  a 
means  to  bypass  protein-truncation8–11  resulting  from  the 
c.2991+1655A>G mutation, we assessed the efficacy of anti-
sense oligonucleotides (AONs) as splice switching oligonu-
cleotides to correct the abnormal splicing in cell lines of LCA 
patients harboring the mutation.
Results
Expression levels of CEP290 mRNAs
Fibroblasts were derived from skin biopsies of controls (C1–C4), 
heterozygous carriers (S1–S3), and homozygous (P1, P2, and 
P4) or compound heterozygous patients (P3). Expression levels 
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of the wild-type and mutant CEP290 mRNAs were measured 
by quantitative reverse transcription PCR (RT-qPCR) in all 
cell lines. Compared to controls and healthy carriers, patients’ 
fibroblasts expressed reduced yet measurable levels of wild-
type mRNAs (mean relative expression levels of 0.72 ± 0.14, 
0.46 ± 0.06, and 0.16 ± 0.02 in control, carrier, and patient 
cell  lines  respectively;  Figure  1a).  Mutant  mRNAs  were 
detected to low levels in patients and heterozygous carriers 
suggesting degradation through nonsense-mediated mRNA 
decay (NMD). To assess this hypothesis, we compared the 
mean level of expression of the mutant and wild-type alleles 
in the patient P1 cell line before and after treatment with NMD-
inhibitor emetine.12 The significant increase of mutant but not 
wild-type  mRNA  levels  in  cells  treated  with  emetine  sup-
ported the view that the aberrant transcript is prone to NMD   
(P < 0.003; Figure 1b).
Design of AON
Important  parameters  including  guanine-cytosine  content 
influence efficiency of AONs to induce exon skipping.13 Nev-
ertheless, the design of AON remains empiric. We designed 
five 2′-O-methyl-phosphorothioate (2′-OMePs) AONs target-
ing either the donor site (HD26 (+10−11), HD26 (+19−10), and 
HD26 (+7−18)) or exonic splice enhancer (ESE) sequences 
predicted using the ESEfinder program (ESE (+50+70) and 
ESEbis (+90+120); Figure 2).
AON-induced correction of the splice defect
AON  efficacy  was  assessed  by  RT-qPCR  by  measuring 
the level of expression of the wild-type and mutant alleles 
in   control, patient, and carrier cell lines transfected for 24 
hours with 150 nmol/l of AON in the cationic peptide LAH4-
L114 (wt/wt 10/1). The use of AONs resulted in a significant 
increase in wild-type mRNA levels suggesting their ability 
to skip efficiently the aberrant transcript (Supplementary 
Figure S1).
The  ESE  (+50+70)  AON  was  selected  for  further 
experiments  for  its  ability  to  reproducibly  induce  targeted 
  exon-skipping at high levels (Figure 3, Supplementary Fig-
ure S2 and Supplementary Materials and Methods).
To  assess  whether  the  skipping  efficacy  was  dose- 
dependent, we treated patient, carrier, and control cell lines 
with increasing amounts of ESE (+50+70) AON. In carrier- 
and patient-derived cell lines, expression levels of the wild-
type mRNA increased with the amount of AON. At an AON 
concentration of 150 nmol/l, the wild-type mRNA expression 
in  patient  cell  lines  reached  the  levels  measured  in  con-
trols (Figure 4). In contrast, the expression of the wild-type 
CEP290 mRNA was unchanged in control cells whatever the 
AON concentration indicating that it did not interfere with nor-
mal CEP290 splicing (Figure 4).
Furthermore, we showed that the transfection of a sense 
version of the ESE (+50+70) AON (ESEsense (+50+70)) in 
patient, carrier, and control cell lines did not interfere with 
CEP290 splicing (Figure 3).
Fluorescently  labeled  antisense  and  sense  oligonucle-
otides ESE (+50+70) were delivered to cell lines of patient 
P1 to make sure that these results were not due to reduced 
delivery of the sense oligonucleotide. Similar transfection effi-
ciencies (>90%) were observed (Supplementary Figure S3 
and Supplementary Materials and Methods).
When,  patient  P1  fibroblasts  were  subjected  to  ESE 
(+50+70)  AON  treatment  in  the  presence  of  emetine,  the 
expression of the wild-type mRNA increased whereas that 
of the mutant mRNA decreased, supporting the view that 
restored stable wild-type mRNA resulted from resplicing of 
the aberrant mutated NMD-prone mRNA (Supplementary 
Figure S4).
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Figure 1  Relative expression of wild-type and mutant (c.2991+1655A>G) transcripts of the CEP290 gene in patient and control 
fibroblasts derived from skin biopsies. The error bars represent the SD of the mean derived from three independent experiments. Rela-
tive expression levels of wild-type (WT CEP290; plain bars) and c.2991+1655A>G mutant (Mutant CEP290; hatched bars) mRNAs were 
determined by RT-qPCR. Results were normalized using the software geNorm. (a) Basal expression of CEP290 mRNAs in untreated cell 
lines from control individuals (C1–C4), heterozygous unaffected carriers (S1–S3), and LCA patients (P1–P4). A striking reduction in the 
basal level of expression of the wild-type CEP290 mRNAs is observed in patient cell lines compared to controls. Results were normalized 
by using the RPLP0 and GUSB genes as reference. (b) Relative expression levels of the wild-type and mutant CEP290 mRNAs in the 
fibroblasts of homozygous patient P1, before (–) and after (+) treatment with emetine. The significant increase in expression of the mutant 
(Mutant CEP290; hatched bars), but not the wild-type (WT CEP290; plain bars) mRNAs in cells treated with emetine (25 μg/ml) suggests 
the degradation of the mutant mRNAs through NMD mechanisms. Results were normalized using the TBP, RPLP0, and GUSB genes as 
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Finally, RT-qPCR carried out on total RNA extracted from 
cytoplasmic fractions of treated patient P1 cell lines detected 
significant levels of respliced mRNAs supporting transport 
of corrected mRNA in the cytoplasm (Supplementary   Figure 
S5 and Supplementary Materials and Methods).
Together,  these  data  support  dose-dependent  and 
sequence-dependent  ability  of  the  ESE  (+50+70)  AON  to 
induce skipping.
AON-mediated  skipping  induces  increase  in  CEP290 
concentration and improves ciliogenesis
To assess the effect of AON-induced exon-skipping on the 
CEP290 protein amount, we performed western blot analy-
ses. A polyclonal anti-CEP290 antibody raised against the 
carboxy-terminus was used which detects the wild-type but 
not the mutant CEP290 protein.
Transfection  of  patient  and  carrier  cells  using  the  ESE 
(+50+70) AON showed efficient exon-skipping at the mRNA 
level  (Figure  5). Western  blot  analyses  of  the  transfected 
cells showed that ESE (+50+70) AON delivery resulted in an 
increased amount of the CEP290 protein (Figure 5). These 
data give strong support to the view that the increase in the 
wild-type transcript abundance results in an increase of pro-
tein concentration.
Considering the role of CEP290 in cilia assembly and/or 
maintenance,6 patient and control cell lines were subjected 
to a 30 hours-serum starvation to assess their respective 
ability to build a primary cilium. Significantly reduced primary 
cilia expression was found in patient cell lines compared to 
controls (mean 48.6 ± 6.5% versus 83.6 ± 3.2% in controls;   
P = 0.0097; Figure 6).
Interestingly, transfection of the antisense but not the sense 
oligonucleotide increased cilia expression to control levels, 
suggesting improved ciliation (mean 75.3 ± 3.5% versus 78.3 
± 3.4% in controls; P = 0.624) (Figure 6).
Discussion
Mis-splicing is among the most frequent pathogenic mecha-
nisms underlying genetic diseases.15,16 Strategies have been 
developed which allow the modification of splice patterns of 
genes to overcome pathogenic process leading to disease 
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drugs, isoform-specific antibodies, trans-splicing approaches, 
RNA interference and AONs have been investigated for their 
ability to modify splicing in various diseases.15–19 Compared 
to most other molecules, nuclease-protected phosphorothio-
ate AONs are of easy design13 and inexpensive. In addition, 
these splice switching AONs can be widely used to restore 
a  wild-type  genetic  configuration  by  allowing  the  skipping 
of  stray  pseudoexons  that  are  relatively  common  in  most 
genetic  diseases;15 2 ′-OMePS  AONs  have  been  primarily 
used to treat acute diseases over a period of weeks or occa-
sionally months.15 Now, clinical trials aiming at assessing life-
long treatments of various genetic diseases are ongoing.15 
Current  ongoing  trials  in  patients  affected  with  Duchenne 
muscular dystrophy have shown that short-term treatment 
using 2′-OMePS AONs is well tolerated.9,20,21
With  respect  to  diseases  affecting  vision,  it  is  worth 
remembering  that  because  the  eye  is  easily  accessible, 
small, confined, and has an efficient blood-retina barrier, it 
is regarded as an ideal target organ for topical treatment. 
So far, to our knowledge the use of 2′-OMePS AONs is 
restricted to the treatment of acute cytomegalovirus retinitis 
using the FDA approved Vitravene.22 Considering inherited 
diseases of the retina, the promising clinical trial phase of 
gene therapy for LCA due to RPE65 mutations have trig-
gered efforts in developing similar treatments.23 CEP290 
replacement,  whose  development  would  benefit  from 
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available spontaneous animal models mimicking the human 
disease (rd16 mouse and rdAc Abbyssinian cat),24,25 is an 
attractive option to treat LCA patients harboring CEP290 
mutations, including the common c.2991+1655A>G muta-
tion. However, CEP290 may be expressed in at least 11 
alternative  transcripts  most  of  which  are  predicted  to 
encode  proteins  whose  tissular  expression  and  function 
are  unknown  (http://harvester4.fzk.de/harvester/human/
IPI00794/IPI00794668.html).  Restoring  the  wild-type 
genetic  configuration  by  correcting  the  aberrant  splicing 
resulting for the c.2991+1655A>G mutation may thus be 
regarded as a preferable option.
Here, we show that this strategy is efficient to correct abnor-
mal splicing accounted for by the CEP290 c.2991+1655A>G 
mutation in fibroblasts cell lines obtained from LCA patients. 
Interestingly, AONs complementary to either the splice donor 
or  exonic  splice  enhancer  sites  cause  a  three  to  4.5-fold 
upregulation of wild-type mRNA in patient-derived fibroblasts 
to levels equaling that in wild-type cells indicating a signifi-
cant degree of flexibility in the design of future therapeutic 
oligonucleotides.
Western  blot  analyses  indicated  that  despite  signifi-
cant  upregulation  of  wild-type  mRNA  in  patient  cells,  as 
measured  by  RT-qPCR,  protein  levels  were  moderately 
increased  (Figure  5).  Discrepancies  between  have  been 
previously  reported.26,27  Slow  synthesis  of  large  proteins, 
post-transcriptional, and post-translational regulations have 
been considered to explain these discrepancies.28,29 Consid-
ering that the increase in restored stable wild-type CEP290 
mRNA arises from nuclear resplicing of the aberrant mutated 
NMD-prone mRNA (Supplementary Figure S4) and that 
significant levels of respliced mRNA were measured in cyto-
plasmic fractions of AON-treated cells (Supplementary Fig-
ure S5), these hypotheses are likely to account at least in 
part to the discrepancy between mRNA and protein abun-
dance increase.Molecular Therapy–Nucleic Acids
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Recently, we reported that CEP290 mutations, including 
the c.2991+1655A>G change, are expressed in nasal epi-
thelial cells of LCA patients.30 In accordance with the func-
tion of CEP290 in cilia assembly and/or maintenance,6 we 
evidenced consistent ciliary defects in nasal ciliated cells of 
patients. Most of these cells presented reduced numbers of 
cilia, most of which were shorter than normal and presented 
various axonemal defects.30 We report here, that in con-
trast to control cells, high numbers of patient cells display 
no primary cilium even after a 30 hours-serum starvation, 
suggesting  that  the  CEP290  c.2991+1655A>G  mutation 
alters the ciliation process in the cells. Most interestingly, 
the  results  we  report  here  show  that,  despite  a  moder-
ate increase in protein abundance compared to respliced 
mRNAs, the use of AON is able to improve significantly cili-
ation in patient cell lines supporting the therapeutic poten-
tial of this strategy.
Finally, the efficiency and absence of major side-effect of 
intravitreal  injections  of  FDA-approved Vitravene22  to  treat 
acute cytomegalovirus retinitis is an encouragement to con-
tinue the development of this promising AON-induced exon-
skipping strategy to bypass the most common LCA-causing 
mutation.
Materials and methods
Transfection agent and AONs. The 26 residues long cationic 
transfecting  peptide  LAH4-L114  (KKALLAHALHLLALLAL-
HLAHALKKA) was prepared by automated solid-phase syn-
thesis on Millipore 9050 or ABI 431 synthesizers using Fmoc 
Chemistry (a kind gift by Andrew J. Mason and Burkhard 
Bechinger). The  2′-O-methyl  RNA  phosphorothioate  oligo-
nucleotides were obtained from Sigma-Aldrich (St Quentin 
Fallavier, France) (Figure 2).
Cell  culture  and  transfection  of  AONs.  Skin  biopsies 
were  obtained  from  four  LCA  patients  harboring  the 
c.2991+1655A>G  mutation  (3/4  homozygous,  P1,  P2, 
P4;  1/4  compound  heterozygous  with  the  c.5850delT, 
p.Phe1950LeuFsX14  mutation  P3),  three  heterozygous 
unaffected carriers (S1–S3), and control individuals (C1–C4). 
Written informed consent was obtained for each individual 
and research was approved by institutional review board. 
Primary  fibroblasts  were  isolated  by  selective  trypsiniza-
tion and proliferated at 37 °C, 5% CO2 in Opti-MEM Gluta-
max I medium (Invitrogen, St Aubin, France) supplemented 
with  10%  fetal  bovine  serum  (Invitrogen),  1%  ultroser  G 
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Figure 6  Effect of exon-skipping on ciliogenesis. (a) Nuclei, cilia, and basal bodies of untreated cell lines and fibroblasts transfected 
with the ESEsense(+50+70) or ESE(+50+70) oligonucleotides were labeled using DAPI (blue), anti-acetylated–tubulin (green). and anti-
γ−tubulin (red) antibodies, respectively (right panel). Bar = 5 μm. (b) The proportions of fibroblasts presenting a primary cilium among cells 
were calculated by numbering at least 200 cells in at least four fields (mean n = 9) from two independent experiments. AON-mediated 
exon-skipping of the mutant cryptic CEP290 exon on messenger RNAs resulted in increased proportions of cells harboring a primary 
cilium for all four patients (statistically significant in 3/4 patients’ cell lines P1, P2, P3). Data are presented using bowplot graphical view. 
Line running horizontally within the box represents the median. The upper and lower limits of the box are formed by 25th (lower quartile 
Q1) and 75th (upper quartile Q3) percentile values, respectively. The tips of the whiskers extending from the box are the smallest and the 
largest observations, respectively. Statistical analyses were carried out by analysis of variance (ANOVA) and PLSD Fisher test (ANOVA, 
Statview Software, version 5). AON, antisense oligonucleotide; DAPI, 4′,6-diamidino-2-phenylindole; ESE, exonic splice enhancer; PLSD, 
protected list significant difference.www.moleculartherapy.org/mtna
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substitute  serum  (Pall,  Saint-Germain-en-Laye,  France), 
and  1%  streptomycin/penicillin  (Invitrogen).  Fibroblasts 
between passage 7 and 9 were plated at 4 × 105 cells/
well in 6-well plates 24 hours before transfection. Cells at 
80%  confluence  were  transfected  with  2′-OMePS  AONs 
(150 nmol/l) in Opti-MEM using LAH4-L1 at a 1:10 (wt:wt) 
AON:peptide ratio. After 3 hours of incubation at 37 °C, the 
transfection medium was replaced by fresh culture medium. 
For the inhibition of NMD, 25 μg/ml of emetine dihydrochlo-
ride hydrate (Sigma-Aldrich) was added to the fresh culture 
medium for 12 hours.
RNA extraction and cDNA synthesis. Twenty-four hours after 
transfection, the transfected and untreated cells were pro-
cessed. Total RNA was extracted using the RNeasy Mini Kit 
(Qiagen, Courtaboeuf, France) according to manufacturer’s 
protocol. All samples were DNase treated by the RNase-free 
DNase  set  (Qiagen,  Courtaboeuf,  France).  Concentration 
and purity of total RNA was assessed using the Nanodrop-
8000 spectrophotometer (Thermo Fisher Scientific, Illkirch, 
France) before storage at −80 °C. Qualitative analysis of 
total RNA was performed using the Bioanalyzer 2220 (RNA 
6000 Nano kit; Agilent Technologies, Massy, France) to ver-
ify that the RNA integrity number was between 8 and 10. 
First-stranded  cDNA  synthesis  was  performed  from  500 
ng of total RNA extracted using Verso cDNA kit (Thermo 
Fisher Scientific) with random hexamer:anchored oligo(dT) 
primers at a 3:1 (vol:vol) ratio according to the manufac-
turer’s instructions. A non-RT reaction (without enzyme) for 
one sample was prepared to serve as control in RT-qPCR 
experiments.
RT-qPCR. To measure the level of expression of CEP290 
mRNAs, the wild-type and mutant transcripts were ampli-
fied as 93 and 117 bp fragments, respectively. Regions of 
132, 80, 84, 101, and 95 bp within the human TATA box-
binding  protein  mRNA  (TBP,  NM_003194),  the  human 
β-2-microglobulin mRNA (B2M, NM_004048.2), the human 
β-glucuronidase mRNA (GUSB, NM_000181.3), the human 
hypoxanthine phosphoribosyltransferase 1 mRNA (HPRT1, 
NM_000194),  and  the  human  P0  large  ribosomal  protein 
mRNA (RPLP0, NM_001002.3) were used for normalization, 
respectively. A 99 bp fragment of the human albumin gene 
(ALB, NM_000477) was used to control the non-contami-
nation of cDNAs by genomic DNA. Primers were designed 
using  the  Oligo  Primer  Analysis  Software  v.7  available  at 
http://www.oligo.net. The specificity of primer pairs to PCR 
template sequences was checked against the NCBI data-
base  using  the  Primer-BLAST  software  (http://www.ncbi.
nlm.nih.gov/tools/primer-blast).  Primer  sequences  were  as 
follows:  CEP290wt  forward,  5′-tgactgctaagtacagggacatct
tg-3′;  CEP290wt  reverse,  5′-aggagatgttttcacactccaggt-3′; 
CEP290mt forward, 5′-ctggccccagttgtaatttgtga-3′; CEP290mt   
reverse, 5′-ctgttcccaggcttgttcaatagt-3′; reference   genes TBP   
forward, 5′-tgcacaggagccaagagtgaa-3′; TBP reverse, 5′-caca 
tcacagctccccacca-3′;  B2M  forward,  5′-cctggaggctatccagcgt 
act-3′;  B2M  reverse  5′-tcaggaaatttgactttccattctct-3′;  GUSB 
forward, 5′-gcggtcgtgatgtggtctgt-3′; GUSB reverse, 5′-gtgagc 
gatcaccatcttcaagt-3′;  HPRT1  forward,  5′-accagtcaacaggg
gacataaaagta-3′;  HPRT1  reverse,  5′-tttgccagtgtcaattatatct
tcca-3′;  RPLP0  forward,  5′-ttctcgttcctggagggtgt-3′;  RPLP0 
reverse, 5′-cgttgatgatagaatggggtactgat-3′; ALB forward 5′-a
tatttccttgtcatcagggttcaga-3′; ALB reverse 5′-accttattggatagc
ccagatacaga-3′.
cDNAs  (5  μl  of  a  1:25  dilution  in  nuclease-free  water) 
were  subjected  to  real-time  PCR  amplification  in  a  buffer 
(20 μl) containing MESA BLUE qPCR Master Mix Plus for 
Sybr  Assay  (Eurogentec,  Angers,  France)  and  300  nmol/l 
of forward and reverse primers, on a Taqman 7900 HT Fast 
Real-Time PCR System (Applied Biosystems, Courtaboeuf, 
France) under the following conditions: Taq polymerase acti-
vation and initial denaturation at 95 °C for 5 minutes, followed 
by 50 cycles for 15 seconds at 95 °C, and 1 minute at 65 
°C. The specificity of amplification products was determined 
from melting curve analysis performed at the end of each run 
using a cycle at 95 °C for 15 seconds, 65 °C for 15 seconds, 
and 95 °C for 15 seconds. Data were analyzed using the SDS 
2.3 software (Applied Biosystems).
For each cDNA sample, the mean of quantification cycle 
(Cq)  values  was  calculated  from  triplicates  (SD  <0.5  Cq). 
CEP290 expression levels were normalized to the “normal-
ization factor” obtained from the geNorm software for Micro-
soft Excel31 which uses the most stable reference genes and 
amplification efficiency estimates calculated for each primer-
pair using fourfold serial dilution curves (1:5, 1:25, 1:125, 
1:625).  No  reverse  transcriptase  (non-RT),  no  template 
  control (NTC) reactions, and non-contamination of cDNAs 
by genomic DNA (ALBh) were used as negative controls in 
each run (Cq values NTC = undetermined, non-RT >40 and 
ALBh >40).
The quantitative data are the means ± SEM of three inde-
pendent experiments and these are presented as ratio among 
values for individual mRNAs. The significance of variations 
among samples was estimated using the protected list sig-
nificant difference of Fisher according to the significance of 
analysis of variance test (Statview Software, version 5; SAS 
Institute, Cary, NC).
Western blot analysis. Cells were harvested 24 hours after 
transfection and lysed in a Triton/SDS buffer (25 mmol/l Tris-
base pH 7.8, 1 mmol/l DTT, 1 mmol/l EDTA, 15% Glycerol, 8 
mmol/l MgCl2, 1% Triton, and 1% SDS) containing complete 
protease  inhibitor  cocktail  (Roche,  Boulogne-Billancourt, 
France) on ice for 30 minutes with repeated mixing. Released 
DNA was fragmented by 20 seconds of Ultra-turrax homog-
enizer (Ika-Werke, Staufen, Germany) and the lysates were 
centrifuged (15,000g at 4 °C for 10 minutes). Protein concen-
trations were determined from the detergent-soluble fractions 
using the DC Protein Assay kit according to the manufacturer 
protocol  (Bio-Rad,  Marnes  la  Coquette,  France).  Proteins 
(125 μg) were denatured at 90 °C for 10 minutes in 4X pre-
mixed protein sample buffer (XT sample Buffer; Bio-Rad) and 
separated by electrophoresis (50 V for 30 minutes followed 
by 140 V for 90 minutes at room temperature) on NuPAGE 
3–8% Tris Acetate gels (Invitrogen). Proteins were transferred 
(100 V, 2 hours at 4 °C) to Immobilon-P PVDF membranes 
(Millipore, Molsheim, France). Membranes were blocked with 
phosphate-buffered saline (PBS) 0.5% Tween-20/5% dry milk 
powder and incubated overnight at 4 °C under agitation with 
polyclonal  rabbit  anti-human  CEP290  (Novus  Biologicals, Molecular Therapy–Nucleic Acids
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Littletown, CO) or monoclonal mouse anti-α-tubulin (Sigma-
Aldrich) primary antibodies in 1:1,800 and 1:500,000 dilu-
tions, respectively. Membranes were washed three times in 
PBS  0.5% Tween-20  solution  (15  minutes)  and  incubated 
for 1 hour at room temperature with HRP-conjugated don-
key anti-rabbit and sheep anti-mouse immunoglobulins sec-
ondary antibodies (Amersham GE Healthcare, Courtaboeuf, 
France) in 1:10,000 dilutions, respectively. ECL Western Blot-
ting  Detection  Reagents  (Amersham  GE  Healthcare)  was 
applied according to the manufacturer’s instructions and the 
blot was exposed to Amersham Hyperfilm ECL (Amersham 
GE Healthcare). The relative expression of the CEP290 pro-
tein was estimated by densitometry using α-tubulin as ref-
erence on a G:Box from Syngene with the GeneSnap and 
GeneTool Softwares.
Immunofluorescence microscopy. Fibroblasts were seeded 
at 2.5 × 105 cells/well on glass coverslips in 12-well plates, 
24 hours before transfection with the ESEsense (+50+70) 
and  ESE  (+50+70)  oligonucleotides,  in  the  conditions 
described  previously.  Ten  hours  after  transfection,  cells 
were  washed  with  PBS  and  incubated  for  30  hours  in 
serum-free medium (37 °C, 5% CO2). Untreated fibroblasts 
were  processed  in  the  same  conditions.  Subsequently, 
cells  were  fixed  in  ice-cold  methanol  (5  minutes  at  −20 
°C) and washed twice in PBS. Cells were permeabilized 
in PBS supplemented with 3% bovine serum albumin and 
0.1% Triton for 1 hour at room temperature before being 
incubated overnight at 4 °C in permeabilization buffer con-
taining (rabbit anti-γ-tubulin (1:1,000), mouse monoclonal 
anti-acetylated  tubulin  (1:1,000);  Sigma-Aldrich)  primary 
antibodies. After three washes with PBS, cells were incu-
bated  for  1  hour  at  room  temperature  in  permeabiliza-
tion  buffer  containing  secondary  antibodies  (Alexa-Fluor 
594–  and  Alexa-Fluor  488–  conjugated  goat  anti-rabbit 
IgG  (1:1,000)  and  goat  anti-mouse  IgG  (1:1,000);  Invit-
rogen,  Life Technologies,  St  Aubin,  France)  followed  by 
three  washes  with  PBS.  A  mounting  media  containing 
4′,6-diamidino-2-phenylindole  (DAPI)  (DAPI  Fluoromount 
G; Southern Biotech, Birmingham, AL) was used to label 
nuclei. Immunofluorescence images were obtained using 
a Leica DM IRBE microscope and a MicroPublisher 3.3 
RTV camera (Q-Imaging France, Bayonne, France). The 
final images were generated using the Cartograph version 
7.2.3 (Microvision Instruments, Evry, France) and ImageJ 
(National Institutes of Health, Bethesda, MA). The percent-
age of ciliated cells was calculated from two independent 
experiments (n > 200 cells for each cell line). The signifi-
cance of variations among samples was estimated using 
the protected list significant difference of Fisher according 
to the significance of the analysis of variance test (Statview 
Software, version 5).
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